Reviews/Ssris and Snris/Sertraline and paroxetine reduce PTSD symptom severity versus placebo
· SS-ANX-03 · v2
This claim has two halves: that sertraline works and that paroxetine works, both compared with a dummy pill, for easing PTSD symptoms. The included evidence backs the sertraline half with two proper placebo-controlled trials: one showing sertraline eased acute symptoms more than placebo [5], the other showing it kept people well and cut relapse [4]. But no eligible head-to-head trial of paroxetine against placebo made it into this set of papers; paroxetine only turns up inside broader review articles that were set aside. Because the claim asks for both drugs to be shown effective, the panel could not treat the whole statement as settled when half of it had no primary evidence here. The sertraline evidence is also drawn from fairly narrow and small patient groups, which limits how far it stretches.
Two independent double-blind placebo-controlled sertraline RCTs favour sertraline: [5] (N=70, combat-related PTSD in Iranian veterans) reports significantly greater reductions in IES-R and CGI-S scores (p<0.001) and far more responders (44% vs 3%, p≤0.001) than placebo; [4] (N=96, 28-week maintenance) reports lower relapse on sertraline than placebo (5% vs 26%). No eligible primary placebo-controlled paroxetine monotherapy trial exists in the corpus; paroxetine appears only within excluded reviews [7], [8], [9], [15]. Several sertraline-containing trials were excluded because they lacked a placebo-only arm or combined sertraline with another agent or psychotherapy [1], [2], [3], [6], [16]. The contested point: The division is the conjunction: the sertraline half is directly supported by [4] and [5], while the paroxetine half has no eligible primary evidence here at all. The sertraline evidence itself rests on a narrow combat-veteran sample [5] and an enriched relapse-prevention design [4] rather than a large civilian acute trial.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim is conjunctive (sertraline AND paroxetine), but no eligible primary placebo-controlled paroxetine monotherapy trial exists in the included corpus; every paroxetine mention sits in excluded reviews. The paroxetine half is unverifiable on this corpus.
[5], the only direct acute sertraline-vs-placebo trial, is a single-centre N=70 study in Iranian combat veterans; the abstract itself notes combat-related PTSD efficacy 'has not yet been proven', limiting generalization to civilian PTSD.
Where it remains uncertain. The claim names both sertraline and paroxetine, yet paroxetine appears only inside excluded review articles [7], [8], [9], [15] with no eligible primary placebo-controlled monotherapy trial.
Aleatory
Eligible evidence rests on small trials (N=70 [5]; N=96 [4]), so chance variation around the observed effects is wide.
Epistemic
The corpus holds no eligible primary placebo-controlled paroxetine monotherapy trial; paroxetine appears only in excluded reviews [7], [8], [9], [15].
Inferential
[4] is a 28-week relapse-prevention design in enriched responders, so it speaks to sustaining improvement rather than the acute symptom reduction the claim asserts.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows sertraline sustains symptom improvement versus placebo over 28 weeks (maintenance design).
“The results provide evidence for the ability of sertraline both to sustain improvement in PTSD symptoms and to provide prophylactic protection against relapse.”
Panel auditInternal validity: high · scope of inference: PTSD patients who had already responded to acute sertraline, in a relapse-prevention phase.Key limitations: relapse-prevention not acute severity · enriched responder population
Direct acute evidence that sertraline reduces PTSD symptom severity versus placebo (N=70 combat veterans).
“The number of responders in the sertraline group was significantly higher than in the placebo group (44% v. 3%, p≤0.001)”
Panel auditInternal validity: high · scope of inference: Iranian male veterans with combat-related PTSD.Key limitations: combat veteran population may not generalize · modest sample
2 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A conjunctive claim cannot exceed its unsupported conjunct, so strong sertraline evidence is capped by the complete absence of eligible paroxetine-vs-placebo data.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No eligible paroxetine-vs-placebo monotherapy trial. The claim names paroxetine, but the corpus contains no eligible primary placebo-controlled paroxetine monotherapy trial; the half cannot be confirmed here. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Include or conduct a double-blind placebo-controlled RCT of paroxetine monotherapy for PTSD reporting symptom-severity change.
Open question: Does paroxetine monotherapy reduce PTSD symptom severity versus placebo? Why it is still open: No eligible primary placebo-controlled paroxetine monotherapy trial is in the corpus; paroxetine appears only in excluded reviews [7], [8], [9], [15].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19